Atherosclerotic cardiovascular disease

This real-world study is following 7,000 Chinese adults with established heart disease to see if adding Repatha® (a cholesterol-lowering injection) to their usual care reduces major cardiovascular events like heart attacks, strokes, and heart-related death. Participants are eithe…

This large Phase 3 trial is testing whether a drug called inclisiran can reduce major heart problems like heart attacks and strokes in people who already have heart disease. About 17,000 participants are taking either inclisiran or a placebo, along with their usual cholesterol-lo…

This large Phase 3 study tests an injectable drug called lepodisiran in about 17,300 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either already have heart disease or are at high risk for a first heart event. The goal…

This phase 3 trial is testing whether the drug retatrutide can lower the chance of serious heart problems (like heart attacks and strokes) and slow kidney disease in 10,000 overweight adults who already have heart or kidney disease. Participants receive either retatrutide or a pl…

This Phase 3 trial tests whether a daily pill called AZD0780 can safely lower LDL (bad) cholesterol in adults with heart disease or at high risk. About 3,100 participants will receive either AZD0780 or a placebo for 52 weeks, and neither they nor their doctors will know which the…

This study tests inclisiran, a twice-yearly injection, to help people with heart disease or at high risk for it reach their LDL cholesterol goals. It focuses on groups often understudied, like women, Black, Hispanic, and rural patients. The trial enrolls 130 adults and measures w…

This study will test whether sending reminders by text, email, or secure patient portal messages helps people with heart disease or diabetes refill their statin prescriptions. About 22,000 adults who have not refilled their statin in the last 3 months will receive one of these me…

This study follows 600 Belgian adults with atherosclerotic cardiovascular disease who are prescribed inclisiran, a cholesterol-lowering injection, alongside their usual medications. Researchers will measure how much LDL cholesterol drops and how many patients reach their target l…

This study compares two cholesterol-lowering strategies in adults aged 75 and older who have heart or blood vessel disease. One group aims for a very low LDL cholesterol target (below 55 mg/dL) using high-intensity statins, while the other receives standard moderate-intensity sta…

This study looks at different methods to help patients with high cholesterol and heart disease get the right medicines to lower their cholesterol. About 300 adults at high risk will take part. The goal is to see which approach helps more people reach their target LDL cholesterol …

This large phase 3 study tests a new cholesterol-lowering injection called inclisiran in over 16,000 people who have already had a heart attack, stroke, or artery surgery. The goal is to see if it safely reduces the risk of future heart attacks, strokes, or the need for emergency…

This Phase 3 trial is testing an oral drug called MK-0616 (enlicitide decanoate) in about 14,550 people at high risk for heart problems. The drug aims to lower cholesterol and reduce the chance of major events like heart attacks, strokes, and emergency artery procedures. Particip…

This study tests a daily pill (obicetrapib plus ezetimibe) to see if it can reduce fatty plaque buildup in the arteries of 300 adults with heart disease. Participants must already be on cholesterol-lowering therapy but still have high LDL cholesterol and measurable plaque. The tr…

This study follows 116 people who received an experimental gene-editing therapy for heart disease or high cholesterol. Researchers will monitor them for 15 years to track any side effects and how well the treatment controls cholesterol levels. The goal is to understand the long-t…

This study tests a drug called olpasiran in about 7,300 people with heart disease and high levels of a fatty particle called Lp(a). The goal is to see if olpasiran can lower the chance of heart attacks, urgent heart procedures, or death from heart disease compared to a placebo. P…

This study tests whether an electronic alert in the medical record can help doctors prescribe better cholesterol-lowering medications for heart disease patients with high LDL. About 400 patients from a single hospital will be randomly assigned to have their doctor receive the ale…

This study looks at 4,000 adults with prediabetes and heart disease to see if a low-intensity statin combined with ezetimibe is better than a high-intensity statin alone at preventing new diabetes. Participants will be followed to track diabetes development and heart health. The …

This study tests a drug called inclisiran in about 345 Asian patients who have heart disease or are at high risk and still have high LDL (bad) cholesterol despite taking statins. The goal is to see if inclisiran lowers LDL cholesterol more than a placebo over about 11 months, and…

Researchers are studying whether artificial intelligence can extract useful warning signs from coronary CT angiography (CCTA) scans in people with coronary artery disease. The study reviews existing medical records from 3,000 patients across five hospitals who had both a CCTA and…

This large Phase 3 study tests whether inclisiran, a twice-yearly injection, can prevent major heart problems like heart attacks, strokes, and heart-related death in people at high risk who have not yet had such an event. Over 14,000 participants are receiving either inclisiran o…

This large, phase 4 trial is testing whether berberine, a natural compound, can prevent heart disease and diabetes in over 2,000 high-risk adults in China. Participants take berberine or a placebo twice daily, plus receive lifestyle advice. The study tracks blood sugar and heart …

Researchers at University Hospital Freiburg are studying how blood levels of hsCRP and Lp(a), two markers linked to heart disease, change over time in patients who have had these tests more than once. The study asks whether a high result on a first test often returns to normal la…

This observational study follows about 198 patients in Spain who are already taking inclisiran (Leqvio) for high cholesterol linked to heart disease or a genetic condition. Researchers will check if patients reach their LDL cholesterol goals after 6 and 12 months. The goal is to …

This study aimed to see if telling patients and their doctors about calcium buildup in heart arteries (found on lung cancer scans) would lower the chance of death, heart attack, or stroke. It was designed for adults without known heart disease who had a lung scan showing signific…

This study will use advanced heart scans (coronary CT angiography) on 4,000 people with rheumatoid arthritis aged 50-75. The goal is to better understand why people with this condition have higher risks of heart attacks, strokes, and lung problems. Researchers will track particip…

This study was designed to see if a cholesterol-lowering drug called a PCSK9 inhibitor could also reduce inflammation in the arteries of people with heart disease. Researchers planned to use a special imaging scan to measure inflammation. The study was withdrawn before enrolling …